Sparkle Surprise LOL Series Ball!!! Gold Rare in Sealed NEW Queen Independent Other Brand & Character Dolls


  1. Home
  2. Sparkle Surprise LOL Series Ball!!! Gold Rare in Sealed NEW Queen Independent
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
LOL Surprise Sparkle Series Independent Queen NEW Sealed in Rare Gold Ball!!!
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Product Line: L.O.L Surprise! by MGA
Type: Doll, Doll Case, Doll Clothes & Accessories, Doll Playset & Accessories Brand:

MGA

Material: Plastic Character Family: L.O.L. Surprise! Sparkle Series
Doll Size: 4 in Modified Item: No
Recommended Age Range: 3+ Doll Gender: Girl Doll
Features: Full Authentic Set w/ 7 Surprises, Anatomically Correct, Ball Jointed Doll (BJD), Big Eyes, Interactive Ethnicity: Multiracial
Packaging: Original (Unopened)










published on tue nov 09 2021

Sparkle Surprise LOL Series Ball!!! Gold Rare in Sealed NEW Queen Independent Other Brand & Character Dolls

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Sparkle Surprise LOL Series Ball!!! Gold Rare in Sealed NEW Queen Independent Other Brand & Character Dolls

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS